Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 11/20 | 0.41 |
| ▸ | BCHE | P06276 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790980 | 0.94 | ABCG2 (0.46) | ABCG2HCRTR2ACHEBCHEABCB1 | |
| SCHEMBL8790718 | 0.94 | ABCG2 (0.47) | ABCG2ACHEBCHEMAPTABCB1 | |
| SCHEMBL8790170 | 0.92 | ABCG2 (0.45) | ABCG2HCRTR2ACHEBCHEABCB1 | |
| SCHEMBL8790242 | 0.91 | ABCG2 (0.56) | ABCG2ACHEBCHEMAPTOPRM1 | |
| SCHEMBL8789987 | 0.91 | ABCG2 (0.47) | ABCG2ACHEBCHEMAPTABCB1 | |
| SCHEMBL8789684 | 0.91 | ABCG2 (0.49) | ABCG2MAPTABCB1OPRM1TMEM97 | |
| SCHEMBL8792324 | 0.90 | ABCG2 (0.50) | ABCG2MAPTABCB1OPRM1TMEM97 | |
| SCHEMBL8790519 | 0.90 | ABCG2 (0.48) | ABCG2HCRTR2ACHEBCHEMAPT | |
| SCHEMBL8792167 | 0.89 | ABCG2 (0.47) | ABCG2HCRTR2ACHEBCHEABCB1 | |
| SCHEMBL8789946 | 0.88 | ABCG2 (0.48) | ABCG2HCRTR2ACHEBCHEABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |